ETF Holdings Breakdown of TSHA

Stock Name	Taysha Gene Therapies Inc
Ticker	TSHA(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8776191061

TSHA institutional holdings

The following institutional investment holdings of TSHA have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 175,737 USD 766,213 4.36

2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 175,737 USD 766,213 4.36

Total = 351,474 USD 1,532,426
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	175,737	USD 766,213	4.36
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	175,737	USD 766,213	4.36
Total =	351,474	USD 1,532,426

News associated with TSHA

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.4% After Insider Selling: Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) traded down 4.4% during mid-day trading on Monday following insider selling activity. The company traded as low as $2.97 and last traded at $2.94. 386,568 shares changed hands during trading, a decline of 87% from the average session volume of 2,949,512 shares. The stock […] - 2025-09-17 02:12:53
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Average PT from Analysts: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has earned an average recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in the […] - 2025-09-05 02:52:55
Contrasting Taysha Gene Therapies (NASDAQ:TSHA) & Supernus Pharmaceuticals (NASDAQ:SUPN): Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. Insider & Institutional Ownership 77.7% of Taysha […] - 2025-08-26 05:06:47
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst Upgrade: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report)’s stock price gapped up prior to trading on Wednesday after Wells Fargo & Company raised their price target on the stock from $7.50 to $8.00. The stock had previously closed at $2.91, but opened at $3.06. Wells Fargo & Company currently has an overweight rating on […] - 2025-08-15 02:34:49
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Chardan Capital Analyst Says: Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) had its target price raised by research analysts at Chardan Capital from $9.00 to $10.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s target price points to a potential upside of 230.03% from the company’s […] - 2025-08-14 03:14:56
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of “Buy” from Brokerages: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in […] - 2025-07-14 05:38:47
Taysha Gene Therapies (NASDAQ:TSHA) and Sol-Gel Technologies (NASDAQ:SLGL) Financial Review: Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Profitability This table compares Taysha Gene […] - 2025-07-02 04:22:55
Squarepoint Ops LLC Acquires 108,719 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Squarepoint Ops LLC grew its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 105.4% in the 4th quarter, Holdings Channel reports. The firm owned 211,842 shares of the company’s stock after acquiring an additional 108,719 shares during the quarter. Squarepoint Ops LLC’s holdings in Taysha Gene Therapies were worth $366,000 […] - 2025-06-06 05:16:54
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Insider Buying Activity: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report)’s stock price gapped up before the market opened on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $2.78, but opened at $2.93. Taysha Gene Therapies shares last traded at $2.74, with a volume of 392,262 shares. Specifically, major […] - 2025-06-06 02:07:06
Nuveen Asset Management LLC Cuts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Nuveen Asset Management LLC cut its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 3.6% in the 4th quarter, Holdings Channel reports. The fund owned 546,414 shares of the company’s stock after selling 20,436 shares during the quarter. Nuveen Asset Management LLC’s holdings in Taysha Gene Therapies were worth $945,000 at the […] - 2025-06-05 04:56:49
BNP Paribas Financial Markets Takes $41,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): BNP Paribas Financial Markets acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 23,644 shares of the company’s stock, valued at approximately $41,000. Several other institutional investors and hedge funds have also recently modified their holdings of the company. […] - 2025-06-04 05:48:46
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA): Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock, up from their prior price objective of $6.00. Needham & Company LLC’s price target indicates a potential […] - 2025-06-04 02:42:44
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Holdings Cut by Deutsche Bank AG: Deutsche Bank AG decreased its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 94.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 151,083 shares of the company’s stock after selling 2,409,201 shares during the quarter. Deutsche Bank […] - 2025-06-02 04:52:51
JMP Securities Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price: Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective boosted by JMP Securities from $5.00 to $6.00 in a research note published on Thursday,Benzinga reports. They currently have a market outperform rating on the stock. A number of other research analysts have also issued reports on TSHA. Canaccord Genuity Group increased their target […] - 2025-05-30 04:55:04
Reviewing Taysha Gene Therapies (NASDAQ:TSHA) & Quince Therapeutics (NASDAQ:QNCX): Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Quince Therapeutics (NASDAQ:QNCX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Volatility and Risk Taysha Gene Therapies […] - 2025-05-28 02:50:53
Taysha Gene Therapies (NASDAQ:TSHA) vs. Black Diamond Therapeutics (NASDAQ:BDTX) Financial Comparison: Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Taysha […] - 2025-05-23 02:48:59
Hsbc Holdings PLC Has $36,000 Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Hsbc Holdings PLC lifted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 65.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,391 shares of the company’s stock after purchasing an additional 8,076 shares during […] - 2025-05-13 04:26:52
Marshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Marshall Wace LLP reduced its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 71.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 138,111 shares of the company’s stock after selling 347,915 shares during the period. Marshall Wace LLP’s holdings in Taysha Gene Therapies were worth $239,000 at the end of […] - 2025-05-06 04:44:54
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of “Buy” by Analysts: Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) has been given a consensus recommendation of “Buy” by the eight analysts that are covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in […] - 2025-05-05 04:28:56
Renaissance Technologies LLC Makes New $1.52 Million Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA): Renaissance Technologies LLC purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 878,448 shares of the company’s stock, valued at approximately $1,520,000. Renaissance Technologies LLC owned approximately 0.43% of Taysha Gene […] - 2025-04-28 05:05:14
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages: Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued ratings on […] - 2025-04-08 02:33:03
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages: Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued a report on […] - 2025-02-17 04:29:09

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.